STOK
Stoke Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website oketherapeutics.com
- Employees(FY) 117
- ISIN US86150R1077
Performance
+0.67%
1W
-5.01%
1M
+153.5%
3M
+177.03%
6M
+127.0%
YTD
-0.83%
1Y
Profile
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.
Technical Analysis of STOK 2024-05-03
Overview:
In the last 5 trading days, the stock has shown mixed signals across various technical indicators. The trend indicators suggest a neutral to slightly bearish sentiment, while momentum indicators show a potential for a reversal. Volatility indicators indicate a narrowing of price range, and volume indicators reflect a slight increase in...
Recent News & Updates
- 2024-05-07 21:04
- 2024-05-07 10:30
- 2024-05-07 06:53
Stoke Therapeutics First Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
- 2024-05-06 07:00
- 2024-05-05 23:53
- 2024-05-05 20:05
- 2024-05-05 20:05
- 2024-05-05 19:00
- 2024-04-29 10:21
Stoke Therapeutics Appoints Thomas Leggett CFO(MT Newswires)
- 2024-04-29 10:00
- 2024-04-29 08:00
- 2024-04-28 20:00
- 2024-04-25 10:01
- 2024-04-24 22:01
- 2024-04-22 19:45
Garry Menzel joins GHO Capital as Operating Partner(Globenewswire)
- 2024-04-17 08:00
- 2024-04-16 20:00
- 2024-04-04 16:30
- 2024-04-04 04:30
- 2024-03-27 23:40
- 2024-03-27 11:40
- 2024-03-27 08:50
- 2024-03-26 20:50
- 2024-03-26 16:07
Stoke Therapeutics Announces Proposed Public Offering(Business Wire)
- 2024-03-26 11:20
- 2024-03-26 07:49
Stoke shares surge on updated results for Dravet drug(BioPharma Dive)
- 2024-03-26 04:07
Stoke Therapeutics Announces Proposed Public Offering(Businesswire)
- 2024-03-25 19:54
Why Is Stoke Therapeutics (STOK) Stock Up 99% Today?(Investorplace)
- 2024-03-25 17:10
- 2024-03-25 16:01
Page 1 of 5
previousnext